Merit Medical Announces SCOUT Milestone: 750,000 Patients Treated with Wire-Free Technology
Merit Medical Systems (NASDAQ: MMSI) has announced a significant milestone for its SCOUT® Radar Localization technology, which has now been used to treat 750,000 patients worldwide. The wire-free, non-radioactive localization system helps physicians precisely target and remove abnormal breast tissue with accuracy of +/- 1mm.
The company recently introduced SCOUT MD™, a next-generation system featuring four distinct reflector shapes for improved tumor margin mapping. SCOUT technology has been implemented in over 1,100 facilities across 50 countries, with more than 500 cases performed daily and approximately 10,000 cases monthly. The system has been featured in over 100 clinical publications covering nearly 8,500 patients.
Merit Medical Systems (NASDAQ: MMSI) ha annunciato una tappa significativa per la sua tecnologia SCOUT® Radar Localization, ora utilizzata per trattare 750.000 pazienti in tutto il mondo. Il sistema di localizzazione senza fili e non radioattivo aiuta i medici a mirare e rimuovere con precisione il tessuto mammario anomalo con un'accuratezza di +/- 1 mm.
L'azienda ha recentemente introdotto SCOUT MD™, un sistema di prossima generazione che presenta quattro diverse forme di riflettori per una migliore mappatura dei margini tumorali. La tecnologia SCOUT è stata implementata in oltre 1.100 strutture in 50 paesi, con più di 500 casi eseguiti ogni giorno e circa 10.000 casi mensili. Il sistema è stato pubblicato in oltre 100 pubblicazioni cliniche che riguardano quasi 8.500 pazienti.
Merit Medical Systems (NASDAQ: MMSI) ha anunciado un hito significativo para su tecnología SCOUT® Radar Localization, que ya se ha utilizado para tratar a 750,000 pacientes en todo el mundo. El sistema de localización sin cables y no radiactivo ayuda a los médicos a dirigir y eliminar con precisión el tejido mamario anormal con una precisión de +/- 1 mm.
La empresa presentó recientemente SCOUT MD™, un sistema de próxima generación que cuenta con cuatro diferentes formas de reflectores para mejorar el mapeo de márgenes de tumor. La tecnología SCOUT se ha implementado en más de 1,100 instalaciones en 50 países, con más de 500 casos realizados diariamente y aproximadamente 10,000 casos mensuales. El sistema ha sido presentado en más de 100 publicaciones clínicas que abarcan casi 8,500 pacientes.
Merit Medical Systems (NASDAQ: MMSI)가 SCOUT® Radar Localization 기술을 위한 중요한 이정표를 발표했으며, 이제 전 세계적으로 75만 명의 환자를 치료하는 데 사용되었습니다. 무선이고 비방사성 로컬라이제이션 시스템은 의사가 비정상 유방 조직을 정확히 겨냥하고 제거하도록 도와주며 정확도는 ±1mm입니다.
회사는 최근 SCOUT MD™를 도입했으며, 더 나은 종양 경계 매핑을 위한 네 가지 구별된 반사체 모양을 특징으로 하는 차세대 시스템입니다. SCOUT 기술은 50개국의 1,100개 시설 이상에 도입되었으며, 매일 500건 이상, 월 약 10,000건의 사례가 수행되고 있습니다. 이 시스템은 거의 8,500명의 환자를 다루는 100개 이상의 임상 출판물에 소개되었습니다.
Merit Medical Systems (NASDAQ: MMSI) a annoncé une étape importante pour sa technologie SCOUT® Radar Localization, qui est désormais utilisée pour traiter 750 000 patients dans le monde. Le système de localisation sans fils et non radioactif aide les médecins à cibler avec précision et à retirer le tissu mammaire anormal avec une précision de +/- 1 mm.
L'entreprise a récemment présenté SCOUT MD™, un système de prochaine génération présentant quatre formes de réflecteurs distinctes pour améliorer la cartographie des marges tumoriques. La technologie SCOUT est déployée dans plus de 1 100 installations dans 50 pays, avec plus de 500 cas réalisés quotidiennement et environ 10 000 cas mensuels. Le système a été présenté dans plus de 100 publications cliniques couvrant près de 8 500 patients.
Merit Medical Systems (NASDAQ: MMSI) hat einen bedeutenden Meilenstein für seine SCOUT® Radar Localization-Technologie bekannt gegeben, die nun zur Behandlung von 750.000 Patienten weltweit eingesetzt wurde. Das kabellose, nicht radioaktive Lokalisationssystem hilft Ärzten, abnormales Brustgewebe mit einer Genauigkeit von +/- 1 mm präzise zu lokalisieren und zu entfernen.
Das Unternehmen hat kürzlich SCOUT MD™ eingeführt, ein System der nächsten Generation mit vier unterschiedlichen Reflectorformen zur verbesserten Abbildung der Tumorränder. Die SCOUT-Technologie ist in über 1.100 Einrichtungen in 50 Ländern implementiert, mit mehr als 500 Fällen pro Tag und ca. 10.000 Fällen pro Monat. Das System wurde in über 100 klinischen Publikationen vorgestellt, die nahezu 8.500 Patienten abdecken.
Merit Medical Systems (بورصة ناسداك: MMSI) أعلنت عن خطوة فارقة مهمة لتقنيتها SCOUT® Radar Localization، والتي استُخدمت الآن لعلاج 750,000 مريضاً حول العالم. يساعد نظام التوطين اللاسلكي وغير الإشعاعي الأطباء في استهداف وإزالة الأنسجة الثديية غير الطبيعية بدقة تصل إلى ±1 مم.
أعلنت الشركة مؤخرًا عن SCOUT MD™، وهو نظام جيل لاحق يضم أربع أشكال عاكسة مختلفة من أجل تحسين تخطيط حواف الورم. تم تطبيق تقنية SCOUT في أكثر من 1,100 منشأة عبر 50 دولة، مع أكثر من 500 حالة يومياً وحوالي 10,000 حالة شهرياً. ظهر النظام في أكثر من 100 منشور سريري يغطي نحو 8,500 مريض.
Merit Medical Systems (NASDAQ: MMSI)宣布了其SCOUT® Radar Localization技术的一个重要里程碑，该技术现已用于治疗全球范围内的75万名患者。这套无线、无放射性定位系统帮助医生以±1毫米的精度精准定位并切除异常乳腺组织。
公司最近推出了SCOUT MD™，这是一个具有四种不同反射器形状的下一代系统，以改善肿瘤边界的映射。SCOUT 技术已在超过 1,100 家机构、覆盖 50 个国家中得到应用，日处理超过 500 例，月约 10,000 例。该系统已在超过 100 篇临床出版物中被介绍，涵盖近 8,500 例患者。
- Technology has reached significant milestone of 750,000 patients treated worldwide
- High precision with +/- 1mm accuracy in targeting affected tissue
- Wide adoption across 1,100+ facilities in 50 countries
- Strong clinical validation with 100+ publications covering 8,500+ patients
- Introduction of next-generation SCOUT MD™ system with enhanced capabilities
- Steady utilization rate of 500+ cases daily and 10,000 monthly
- None.
Insights
Merit Medical's SCOUT technology reaches 750,000 patients, demonstrating strong market leadership in wire-free breast cancer localization devices.
Merit Medical has achieved a significant commercial milestone with its SCOUT Radar Localization system now used in 750,000 patients worldwide. This achievement validates Merit's leadership position in the wire-free, non-radioactive breast tumor localization market. The technology offers precision targeting within +/- 1mm accuracy, which contributes to more successful surgeries and better patient outcomes.
The SCOUT system's versatility is particularly noteworthy - it can be used in various clinical scenarios: pre or post-chemotherapy, during biopsies, for lymph node marking, and for bracketing larger tumors. This flexibility expands its utility across the cancer care continuum. Merit has also expanded the system's applications beyond breast cancer to include marking any soft tissue site intended for surgical removal.
The market adoption metrics are compelling: SCOUT is used in 50 countries, at over 1,100 facilities, and in approximately 10,000 cases monthly (about 500 daily). The technology has substantial clinical validation, appearing in over 100 clinical publications referencing nearly 8,500 patients.
Merit's recent addition of SCOUT MD to its portfolio represents a strategic expansion of the product line. This next-generation system offers four different reflector shapes with distinct radar signals, enabling more sophisticated tumor mapping and multi-lesion localization.
This milestone demonstrates Merit Medical's established foothold in the breast cancer surgical technology market, with a product that continues to gain adoption based on its clinical utility and precision advantages over traditional wire localization methods.
SCOUT Radar Localization use grows, supporting more successful surgeries and improved patient care
SOUTH JORDAN, Utah, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced a significant milestone for breast cancer treatment: SCOUT® Radar Localization use has reached 750,000 patients worldwide.1
This global achievement coincides with Breast Cancer Awareness Month, a time dedicated to educating the public about the signs and symptoms of the condition, the importance of early detection, and the availability of high-quality treatment options. It is estimated that more than 300,000 new cases of invasive breast cancer will be diagnosed in women this year alone in the United States.2
As a market leader in wire-free non-radioactive localization technology, Merit’s mission this month—and every month—is to reduce the burden that cancer places on patients and their loved ones. Radar localization helps physicians surgically remove abnormal breast tissue while reducing trauma to surrounding healthy tissue. By implanting a tiny reflector, approximately the size of a grain of rice, physicians can use SCOUT to target affected tissue within +/- 1 mm of accuracy, which may result in more successful surgeries and improved patient care.
SCOUT supports multiple treatment needs, including placement in breast tissue and lymph nodes, and can be used pre- or post-neoadjuvant chemotherapy, at time of biopsy, and for bracketing, a technique used to help localize large or multifocal tumors for breast-conserving therapy. The SCOUT indication for use also supports percutaneous placement in soft tissue to mark a biopsy site or a soft tissue site intended for surgical removal, broadening utilization of SCOUT technology outside the traditional use for breast cancer treatment.
To further transform surgical localization, Merit recently added SCOUT MD™ to its portfolio. This next-generation localization system provides four reflector shapes with distinct radar signals, enabling more precise tumor margin mapping and localization of multiple lesions or nodes.
A trusted solution for breast cancer care, SCOUT has been mentioned in more than 100 clinical publications with nearly 8,500 patients referenced throughout. It has been used in 50 countries; more than 500 cases are performed each day, totaling 10,000 cases per month. Over 1,100 facilities worldwide choose SCOUT as their preferred method of wire-free localization.
Learn more about the SCOUT Radar Localization system.
“We’re delighted to see the positive impact SCOUT has on patients’ lives, especially during such a momentous time of the year as Breast Cancer Awareness Month,” said Fred Lampropoulos, Merit Medical’s Chairman and Chief Executive Officer. “At Merit, support for individuals with breast cancer and their loved ones extends beyond October. Every day, through products like SCOUT, we’re able to help more patients become cancer-free, and we’re proud to be a part of that.”
ABOUT MERIT MEDICAL
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,300 people worldwide.
TRADEMARKS
Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.
CONTACTS
PR/Media Inquiries
Sarah Comstock
Merit Medical
+1-801-432-2864 | sarah.comstock@merit.com
Investor Inquiries
Mike Piccinino, CFA, IRC
Westwicke - ICR
+1-443-213-0509 | mike.piccinino@westwicke.com
1. Data on File.
2. National Breast Cancer Foundation. 2024. “Breast Cancer Stats & Facts.” https://www.nationalbreastcancer.org/breast-cancer-facts/
FAQ
How many patients have been treated with Merit Medical's SCOUT Radar Localization technology?
What is the accuracy level of MMSI's SCOUT localization system?
How widely is Merit Medical's SCOUT technology being used globally?
What is new about Merit Medical's SCOUT MD system?
How is Merit Medical's SCOUT technology validated in clinical research?
